Europe PMC

Design of a Recombinant Multivalent Epitope Vaccine Based on SARS-CoV-2 and Its Variants in Immunoinformatics Approaches.

Author information

Affiliations

  • 1. Department of Immunology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi, China.
      Authors
    • Yu M 1
    • Chen Z 1
    • Ding J 1
    (3 authors)
  • 2. Reproductive Medicine Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
      Authors
    • Zhu Y 2
    (1 author)
  • 3. Department of Blood Transfusion, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
      Authors
    • Li Y 3
    (1 author)
  • 4. Clinical Laboratory Center, Xinjiang Uygur Autonomous Region People's Hospital, Urumqi, China.
      Authors
    • Li Z 4
    (1 author)
  • 5. Xinjiang Laboratory of Respiratory Disease Research, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
      Authors
    • Wang J 5
    • Li Z 5
    (2 authors)
    • Show all (6)

Frontiers in Immunology, 06 May 2022, 13:884433
https://doi.org/10.3389/fimmu.2022.884433 PMID: 35603198 PMCID: PMC9120605

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Abstract 

The development of an effective multivalent vaccine against SARS-CoV-2 variants is an important means to improve the global public health situation caused by COVID-19. In this study, we identified the antigen epitopes of the main global epidemic SARS-CoV-2 and mutated virus strains using immunoinformatics approach, and screened out 8 cytotoxic T lymphocyte epitopes (CTLEs), 17 helper T lymphocyte epitopes (HTLEs), 9 linear B-cell epitopes (LBEs) and 4 conformational B-cell epitopes (CBEs). The global population coverage of CTLEs and HTLEs was 93.16% and 99.9% respectively. These epitopes were spliced together by corresponding linkers and recombined into multivalent vaccine. In silico tests, the vaccine protein was a non-allergen and the docking with TLR-3 molecule showed a strong interaction. The results of immune simulation showed that the vaccine may be helpful to initiate both cellular and humoral immunity against all VOC. The optimistic immunogenicity of the vaccine was confirmed in vivo and in vitro finally. Therefore, our vaccine may have potential protection against SARS-CoV-2 and its variants.

Free full text 

loading

Full text links 

Read article at publisher's site: https://doi.org/10.3389/fimmu.2022.884433

Read article for free, from open access legal sources, via Unpaywall: https://www.frontiersin.org/articles/10.3389/fimmu.2022.884433/pdfUnpaywall

Citations & impact 

Impact metrics

27
Citations
Jump to Citations

Citations of article over time

loading

Article citations

loading

Data 

loading

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

    Funding 

    Funders who supported this work.

    Government of Xinjiang Uygur Autonomous Region of China (1)

    • Grant ID: 2021B03003-2

      Loading publications

    National Natural Science Foundation of China (1)

    • Grant ID: 81960373, 81860352, 31560262

      Loading publications

    • Get citation
    • Open PDF
    • Claim to ORCID